1. Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report. Issue 5 (9th April 2019) Authors: Edahiro, Ryuya; Ishijima, Mikako; Kurebe, Hiroyuki; Nishida, Kohei; Uenami, Takeshi; Kanazu, Masaki; Akazawa, Yuki; Yano, Yukihiro; Mori, Masahide Journal: Thoracic cancer Issue: Volume 10:Issue 5(2019) Page Start: 1276 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗